Splicing-Based Predictive Learning for Individual Chemotherapy Evaluation in Colorectal Cancer (SPLICE)
Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY
Colorectal cancer (CRC) remains one of the leading causes of cancer-related mortality worldwide. Although adjuvant chemotherapy improves survival after curative resection, its efficacy varies widely among patients. The absence of reliable predictive biomarkers often leads to overtreatment or undertreatment. This study aims to develop a machine learning-based predictive model for adjuvant chemotherapy response using tumor-derived alternative splicing signatures. By integrating RNA-seq data, splicing isoform and clinical outcomes, this study seeks to identify molecular predictors of treatment response and recurrence risk after surgery.
• Received standard adjuvant chemotherapy after curative resection
• Availability of tumor tissue (FFPE or frozen) before chemotherapy
• Sufficient clinical data for outcome analysis (recurrence, survival)
• Age 18-80 years Stage
Locations
United States
California
City of Hope Medical Center
RECRUITING
Duarte
Contact Information
Primary
Ajay Goel, PhD
AJGOEL@COH.ORG
626-218-3452
Time Frame
Start Date:2024-06-21
Estimated Completion Date:2026-06-18
Participants
Target number of participants:200
Treatments
Non-responders of colorectal cancer (Training Cohort)
Non-responders of colorectal cancer who developed recurrent CRC within 60 months from primary tumor treatment, in the first cohort
Responders of colorectal cancer (Training Cohort)
Responders of colorectal cancer who did not develop recurrent CRC within 60 months from primary tumor treatment, in the first cohort
Non-responders of colorectal cancer, with recurrent disease (Validation Cohort)
Non-responders of colorectal cancer who developed recurrent CRC within 60 months from primary tumor treatment, in the second, independent, validation cohort
Responders of colorectal cancer (Validation Cohort)
Responders of colorectal cancer who did not develop recurrent CRC within 60 months from primary tumor treatment, in the second, independent, validation cohort